AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
delafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 5238 | 189279-58-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Delafloxacin belongs to the fluoroquinolone class of antibacterial drugs and is anionic in nature. The antibacterial activity of delafloxacin is due to the inhibition of both bacterial topoisomerase IV and DNA gyrase (topoisomerase II) enzymes which are required for bacterial DNA replication, transcription, repair, and recombination. Delafloxacin exhibits a concentration-dependent bactericidal activity against gram-positive and gram-negative bacteria in vitro.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.90 | g | O |
| 0.60 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.35 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.33 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.16 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | GRK2,PDK1,PDK2,PDK4 | 4 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK9,DYRK1B,EIF2AK3,GRK2,HIPK2,MAP2K6,MAPK7,MARK4,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM3,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK | 25 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 16, 2019 | EMA | A. Menarini Industrie Farmaceutiche Riunite s.r.l. | |
| June 19, 2017 | FDA | MELINTA THERAPEUTICS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diarrhoea | 72.89 | 66.92 | 24 | 30 | 939166 | 89689227 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01MA23 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
| FDA CS | M0372253 | Fluoroquinolones |
| MeSH PA | D000890 | Anti-Infective Agents |
| FDA EPC | N0000193223 | Fluoroquinolone Antibacterial |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01MA Fluoroquinolones 22 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bacterial infection of skin | indication | 128936008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.78 | acidic |
| pKa2 | 11.32 | acidic |
| pKa3 | 1.05 | Basic |
| pKa4 | 0.46 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 450MG BASE | BAXDELA | MELINTA | N208610 | June 19, 2017 | RX | TABLET | ORAL | 8252813 | Oct. 2, 2026 | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS |
| EQ 300MG BASE/VIAL | BAXDELA | MELINTA | N208611 | June 19, 2017 | RX | POWDER | INTRAVENOUS | 8252813 | Oct. 2, 2026 | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS |
| EQ 300MG BASE/VIAL | BAXDELA | MELINTA | N208611 | June 19, 2017 | RX | POWDER | INTRAVENOUS | 12558349 | March 14, 2034 | TREATING AN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) IN AN OVERWEIGHT OR OBESE PATIENT BY INTRAVENOUSLY (IV) ADMINISTERING 300MG OF DELAFLOXACIN OR A PHARMACEUTICALLY ACCEPTABLE SALT, TWICE A DAY |
| EQ 300MG BASE/VIAL | BAXDELA | MELINTA | N208611 | June 19, 2017 | RX | POWDER | INTRAVENOUS | 12036219 | June 2, 2034 | TREATING AN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) IN AN OVERWEIGHT OR OBESE PATIENT BY INTRAVENOUSLY (IV) ADMINISTERING 300MG OF DELAFLOXACIN OR A PHARMACEUTICALLY ACCEPTABLE SALT, TWICE A DAY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 450MG BASE | BAXDELA | MELINTA | N208610 | June 19, 2017 | RX | TABLET | ORAL | June 19, 2022 | NEW CHEMICAL ENTITY |
| EQ 300MG BASE/VIAL | BAXDELA | MELINTA | N208611 | June 19, 2017 | RX | POWDER | INTRAVENOUS | June 19, 2022 | NEW CHEMICAL ENTITY |
| EQ 450MG BASE | BAXDELA | MELINTA | N208610 | June 19, 2017 | RX | TABLET | ORAL | June 19, 2027 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| EQ 300MG BASE/VIAL | BAXDELA | MELINTA | N208611 | June 19, 2017 | RX | POWDER | INTRAVENOUS | June 19, 2027 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 6315412YVF | UNII |
| 352458-37-8 | SECONDARY_CAS_RN |
| 4036880 | VANDF |
| C2828290 | UMLSCUI |
| CHEBI:751540 | CHEBI |
| TE9 | PDB_CHEM_ID |
| CHEMBL2105637 | ChEMBL_ID |
| 487101 | PUBCHEM_CID |
| DB11943 | DRUGBANK_ID |
| D09330 | KEGG_DRUG |
| CHEMBL2105638 | ChEMBL_ID |
| 9064 | INN_ID |
| C477891 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10799 | IUPHAR_LIGAND_ID |
| C405494 | MESH_SUPPLEMENTAL_RECORD_UI |
| 735011001 | SNOMEDCT_US |
| 735012008 | SNOMEDCT_US |
| 763596009 | SNOMEDCT_US |
| 258700 | MMSL |
| 32817 | MMSL |
| d08601 | MMSL |
| 017249 | NDDF |
| 017250 | NDDF |
| 1927662 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Baxdela | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70842-101 | TABLET | 450 mg | ORAL | NDA | 33 sections |
| Baxdela | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70842-102 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 300 mg | INTRAVENOUS | NDA | 33 sections |